$CGEN

Compugen Ltd Q2 Loss Drops

Compugen Ltd (CGEN) reported a Q2 GAAP net loss of $7.01 million, or $0.07 per share, improving from a $7.34 million loss, or $0.08 per share, a year earlier. Revenue rose 106.3% to $2.60 million from $1.26 million, according to the company.

Original reporting
Published Aug 3, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CGEN
Bearish
medium confidence
Mentioned
$CGEN
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CGENBearishLow
01

Why it matters

Investors will likely weigh the large year-over-year revenue increase against the still-material GAAP net loss of $7.01M.

02

Market read

This is a straightforward earnings datapoint with revenue growth but continued losses, offering limited incremental decision-making without guidance or cash-flow context.

03

What to watch

No cash balance, operating expense trend, guidance, or backlog is provided, so the market may need additional filings to judge whether losses are controllable.

Relevance 5/10Novelty 5/10Timing: Q2 results reported today (2026-08-03)

Background

The article summarizes Compugen’s Q2 GAAP results, comparing them to the prior year.

Company-level read

Ticker impact

$CGENBearishMedium confidence
Context

Compugen reported Q2 GAAP net loss of $7.01M, with revenue up 106.3% to $2.60M, versus prior-year $1.26M.

Expected impact

Likely downside or choppy trading if investors focus on losses outweighing revenue growth.

Evidence & confidence

The article provides only GAAP loss and revenue growth, with no guidance or balance-sheet/cash detail to offset the loss trend.

Market effects

Limited read-through because the article lacks segment, customer, or product details beyond revenue and GAAP loss.

None indicated.

None indicated.

Counterpoint

Revenue more than doubled year over year, which could indicate improving traction that may eventually reduce losses if costs scale slower.

Key entities

  • Compugen Ltd

    Reported Q2 GAAP net loss of $7.01M and revenue of $2.60M, up 106.3% year over year.

Related articles

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$VODMed

Vodafone seeks to cut UK costs by £1 billion by 2032

Vodafone aims to save £1 billion annually in UK costs by 2032, raising its target from £800 million. The company expects mid-to-high single-digit EBITDAaL growth and a threefold increase in operating free cash flow by 2032. CEO Margherita Della Valle cited confidence in the upgraded target.

$LEVIHighAI 9/10

Levi Strauss Lifts Profit Guidance, but Tariff Refund Flatters the Beat

Levi Strauss (LEVI) raised its full-year profit guidance after Q3 adjusted earnings of $0.48 per share beat estimates, though revenue of $1.6B met expectations. The beat was partly due to a $79M tariff refund. Shares closed at $19.51, down 4.97% pre-earnings. The company plans to redeploy $60M into direct-to-consumer initiatives, which make up 45% of revenue. Guidance for gross margin and revenue growth was also adjusted.

$005930.KSMedAI 8/10

Record profits fail to impress Samsung investors

Samsung Electronics reported a record quarterly operating profit of 107.4 trillion won, up 782.5% year-over-year. Despite this, shares fell 2.42% as investors questioned the sustainability of earnings growth. Analysts are divided on the outlook, with some predicting a prolonged memory chip upcycle and others cautioning of a potential downturn. The company plans to return 50% of its free cash flow to shareholders between 2024 and 2026.

$WSMedAI 8/10

Worthington Steel Inc (WS) (Q1 2027) Earnings Call Highlights: Kloeckner Acquisition Drives

Worthington Steel Inc (WS) reported Q1 2027 earnings with $954M net sales, up 9% YoY, and adjusted EBITDA of $111M. The Kloeckner acquisition expanded operations but resulted in a net loss of $7M due to higher interest and purchase accounting impacts. Automotive and agriculture shipments grew, while energy and construction declined. Net debt stands at $1.9B. Management expects synergy benefits post-integration.

$005930.KSMedAI 8/10

Foreign selling and ETF rebalancing drag South Korea stocks despite Samsung beat

South Korea's KOSPI index fell 2.62% to 6,625.93 despite Samsung Electronics(005930) reporting record earnings of 10.74 trillion won. Foreign and institutional selling, ETF rebalancing, and profit-taking drove the decline. Samsung's stock dropped 2.42%, while LG Energy Solution(373220) and Samsung SDI gained. Other major stocks like SK hynix(000660) and Hyundai Motor also fell.